Zealand Pharma hosts conference call on March 7 at 4 pm CET (10 am EST) to present fourth quarter and full year results for 2018

Søborg, DENMARK


Press Release – No. 03 / 2019

 

Zealand hosts conference call on March 7 at 4 pm CET (10 am EST) to present fourth quarter and full year results for 2018

Copenhagen, February 25, 2019 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR no. 20 04 50 78) announces that it will host a conference call on March 7, 2019 at 4 pm CET/10 am EST following the announcement of its Q4 and FY 2018 results.

Interim Chief Executive Officer Adam Steensberg (effective March 1, 2019), and Executive Vice President and Chief Financial Officer Mats Blom, will lead the call, with the corporate management team in attendance. The presentation will be followed by a Q&A session. The conference call will be conducted in English, and the dial-in numbers are:

Denmark:..................... +45 32 72 80 42
United Kingdom:.......... +44 (0) 844 571 8892
United States:.............. +1 631 510 7495
Passcode..................... 5977587

A live audio webcast of the call, including an accompanying slide presentation, will be available via the following link, https://edge.media-server.com/m6/p/2ircikvb, and will be accessible on the Investor section of Zealand’s website (www.zealandpharma.com). Participants are advised to register for the webcast approximately 10 minutes before the scheduled start. A recording of the event and a transcript will be available on the Investor section of Zealand’s website after the call.


For further information, please contact:

Adam Steensberg, Interim Chief Executive Officer (eff. March 1, 2019),
Executive Vice President and Chief Medical & Development Officer
Tel: +45 50 60 36 01, e-mail: ast@zealandpharma.com

Mats Blom, Executive Vice President, Chief Financial Officer
Tel: +45 31 53 79 73, e-mail: mabl@zealandpharma.com


About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma. 

Attachment


Attachments

03-19_0225 FY2018 Conference call